379 related articles for article (PubMed ID: 16244521)
1. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Balaban B; Matthews DJ; Clayton GH; Carry T
Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
[TBL] [Abstract][Full Text] [Related]
2. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
Alman BA; Raza SN; Biggar WD
J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
[TBL] [Abstract][Full Text] [Related]
3. Deflazacort treatment of Duchenne muscular dystrophy.
Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
[TBL] [Abstract][Full Text] [Related]
4. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
[TBL] [Abstract][Full Text] [Related]
5. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
[TBL] [Abstract][Full Text] [Related]
6. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
[No Abstract] [Full Text] [Related]
8. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
Wong BL; Christopher C
J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
[TBL] [Abstract][Full Text] [Related]
10. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.
Houde S; Filiatrault M; Fournier A; Dubé J; D'Arcy S; Bérubé D; Brousseau Y; Lapierre G; Vanasse M
Pediatr Neurol; 2008 Mar; 38(3):200-6. PubMed ID: 18279756
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
[TBL] [Abstract][Full Text] [Related]
12. Steroid therapy and cardiac function in Duchenne muscular dystrophy.
Markham LW; Spicer RL; Khoury PR; Wong BL; Mathews KD; Cripe LH
Pediatr Cardiol; 2005; 26(6):768-71. PubMed ID: 15990951
[TBL] [Abstract][Full Text] [Related]
13. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
Biggar WD; Harris VA; Eliasoph L; Alman B
Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
[TBL] [Abstract][Full Text] [Related]
16. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD; Skalsky A; McDonald CM
J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
[TBL] [Abstract][Full Text] [Related]
17. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
[TBL] [Abstract][Full Text] [Related]
18. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
McAdam LC; Mayo AL; Alman BA; Biggar WD
Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512
[TBL] [Abstract][Full Text] [Related]
19. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.
Angelini C; Peterle E
Acta Myol; 2012 May; 31(1):9-15. PubMed ID: 22655511
[TBL] [Abstract][Full Text] [Related]
20. Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment.
Merlini L; Cecconi I; Parmeggiani A; Cordelli DM; Dormi A
Acta Myol; 2020 Dec; 39(4):200-206. PubMed ID: 33458575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
